We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Malignant melanoma treatment and follow-up management during COVID-19 pandemic.
- Authors
Luminita Zob, Daniela; Nitipir, Cornelia; Mazilu, Laura; Niculai, Gabriela; Moldovan, Alina; Kajanto, Lidia; Suceveanu, Andra-Iulia; Florin, Radu; Voinea, Silviu; Savin, Viorel; Constantinescu, Amalia; Grigorescu, Alexandru; Mihăilă, Raluca; Lucia Stănculeanu, Dana
- Abstract
Melanoma is a public health issue due to its increasing incidence and young age of diagnosis. There are three types of malignant melanoma: cutaneous, uveal and mucosal, all with different incidence, prognosis and management. Some malignant melanoma treatments – including chemotherapy, targeted therapies, immunotherapy and radiation – can change the immune response. People with weakened immune systems or with lung problems due to radiotherapy pneumonitis or immune-mediated pneumonitis or with lung metastases have a much higher risk of complications if they are infected with SARS-CoV-2. On the 20th of April 2020, there were reported 2,444,209 coronavirus cases and 167,986 deaths. There are various recommendations amidst COVID-19 pandemic on diagnosis and treatment of patients with different kinds of solid tumors. The ethical principle that should guide our medical decisions should be primum non nocere, respecting patient wish and trying to do what is best for him/her, with fair allocation of resources. In this review, we wanted to evaluate and reinforce the recommendations on melanoma patients' management by searching for different medical societies' recommendation. We found guidelines on how to manage melanoma patients in different stages of the disease and how to treat best patients, minimizing exposure to infection.
- Subjects
COVID-19 pandemic; MELANOMA; MEDICAL societies; SARS-CoV-2; UVEA cancer; RESOURCE allocation
- Publication
Oncolog-Hematolog, 2020, Issue 51, p40
- ISSN
2066-8716
- Publication type
Article
- DOI
10.26416/onhe.51.2.2020.3193